Drugs / CIC Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06291857 | Dec 2024 → Dec 2025 | COVID-19 | Novavax | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2025-06-11 | Novavax | Results Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial novavax.com ↗
Both stand-alone flu and CIC vaccine candidates induced robust immune responses to the vaccine strains (2.4-5.7-fold over baseline). |
| 2024-11-12 | Novavax | Regulatory Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights novavax.com ↗
In November 2024 , the U.S. Food and Drug Administration (FDA) removed the clinical hold on Novavax's Investigational New Drug (IND) application for its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates. |
| 2024-11-11 | Novavax | Regulatory U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial novavax.com ↗
The FDA has cleared the Company to begin enrolling the planned Phase 3 trial following the determination that Novavax satisfactorily addressed all clinical hold issues. |
| 2023-05-09 | Novavax | Results Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses novavax.com ↗
The CIC vaccine candidate achieved both immunoglobulin G (IgG) and neutralizing levels comparable to Novavax's prototype COVID vaccine (NVX-CoV2373). |
| 2022-11-08 | Novavax | Results Novavax Reports Third Quarter 2022 Financial Results and Operational Highlights novavax.com ↗
Announced positive cellular immunity results of CIC Phase 1/2 trial following initial results announced in April, demonstrating ability to generate immune responses, including both antibody and polyfunctional CD4+ T-cell responses, against SARS-CoV-2 and homologous and heterologous influenza strains |
| 2022-10-13 | Novavax | Results Novavax COVID-19-Influenza Combination Vaccine Candidate Induced Antibody and T-Cell Responses Against SARS-CoV-2 and Homologous and Heterologous Influenza Strains novavax.com ↗
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced positive results from the Phase 1/2 clinical trial of its COVID-19-Influenza Combination (CIC) vaccine candidate. |
| 2022-05-09 | Novavax | Results Novavax Reports First Quarter 2022 Financial Results and Operational Highlights novavax.com ↗
Announced initial results of CIC Phase 1/2 trial, combining NVX-CoV2373 and quadrivalent influenza vaccine candidate |
| 2022-04-20 | Novavax | Results Initial Results from Novavax' COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine novavax.com ↗
The CIC trial demonstrated that formulating the combination vaccine is feasible, well-tolerated and immunogenic. |
All press releases naming this drug 8 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CIC Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06291857 ↗ |
| Modality | Vaccine | “new combination vaccine” NCT06291857 ↗ |
| Route | Intramuscular | “single intramuscular (IM) injection on Day 0” NCT06291857 ↗ |